| Hympavzi |
Marstacimab | 马塔西单抗 | B02BX11 | | Pfizer Europe MA EEIG | Opinion |
| Absimky |
ustekinumab | 乌司奴单抗 | L04AC05 | | Accord Healthcare Ltd | Opinion |
| Alhemo |
concizumab | 康赛珠单抗 | B02BX10 | | Novo Nordisk A/S | Opinion |
| Buprenorphine Neuraxpharm |
buprenorphine | 盐酸丁丙诺啡 | N07BC01 | | Neuraxpharm Pharmaceuticals S.L. | Opinion |
| Fluad |
influenza vaccine (surface antigen, inactivated, adjuvanted) | | J07BB02 | | Seqirus Netherlands B.V. | Opinion |
| Flucelvax |
influenza vaccine (surface antigen, inactivated, prepared in cell cultures) | | J07BB02 | | Seqirus Netherlands B.V. | Opinion |
| Siiltibcy |
Mycobacterium tuberculosis derived antigens (rdESAT-6 / rCFP-10) | | | | Serum Life Science Europe GmbH | Opinion |
| Imuldosa |
ustekinumab | 乌司奴单抗 | L04AC05 | | Accord Healthcare S.L.U. | Opinion |
| Epixram |
levetiracetam | | N03AX14 | | Neuraxpharm Pharmaceuticals S.L. | Application withdrawn |
| Apremilast Viatris |
apremilast | 阿普米司特 | L04AA32 | | | Application withdrawn |
| Korjuny |
catumaxomab | 卡妥索单抗 | L01XC09 | | Lindis Biotech GmbH | Opinion |
| Eltrombopag Viatris |
eltrombopag | 艾曲泊帕乙醇胺 | B02BX05 | | Viatris Limited | Opinion |
| Wainzua |
eplontersen | | N07XX21 | | AstraZeneca AB | Opinion |
| Hetronifly |
serplulimab | 斯鲁利单抗 | L01FF12 | | Henlius Europe GmbH | Opinion |
| Pomalidomide Teva |
pomalidomide | 泊马度胺 | L04AX06 | | Teva GmbH | Opinion |
| Opuviz |
aflibercept | 阿柏西普 | S01LA05 | | Samsung Bioepis NL B.V. | Opinion |
| Afqlir |
aflibercept | 阿柏西普 | S01LA05 | | Sandoz GmbH | Opinion |
| Penbraya |
Meningococcal group A, B, C, W and Y vaccine | | J07AH | | Pfizer Europe MA EEIG | Opinion |
| Theralugand |
lutetium (177Lu) chloride | 氯化镥[177Lu] | V10X | | Eckert & Ziegler Radiopharma GmbH | Opinion |
| Elahere |
mirvetuximab soravtansine | 索米妥昔单抗 | L01FX26 | | AbbVie Deutschland GmbH & Co. KG | Opinion |
